Panacea Index Logo

Command Palette

Search for a command to run...

Eight-month intensive meditation-based intervention improves refractory hallucinations and delusions and quality of life in male inpatients with schizophrenia: a randomized controlled trial.

Psychiatry and clinical neurosciences
April 1, 2024
Ting Xue et al. (15 authors)
Randomized Controlled TrialJournal ArticleHuman StudyClinical
Study Details

Study Goal

The researchers aimed to determine whether an 8-month daily-guided intensive meditation-based intervention (iMI) could reduce persistent hallucinations/delusions and improve health-related quality of life in male inpatients with treatment-refractory schizophrenia.

Results Summary

The iMI significantly improved reduction rates in psychotic symptoms (PANSS scores) and increased health-related quality of life (SF-36) and mindfulness skills (FFMQ) compared to general rehabilitation alone, with more pronounced benefits after 8 months versus 3 months.

Population

Male inpatients with schizophrenia and treatment-refractory hallucinations/delusions (TRHDs).

Effective Dosage

Daily-guided intensive meditation (specific duration/frequency not detailed beyond "daily").

Duration

8 months.

Interactions

None mentioned.

Extracted Claims (11)
InterventionDirectionEndpointPopulationDosageImpactClaim #
8-month daily-guided intensive meditation-based intervention (iMI) plus general rehabilitation program (GRP)
decrease
PANSS total score
male inpatients with schizophrenia with treatment-refractory hallucinations and delusions (TRHDs)
-
significantly improved the reduction rates
#1
8-month daily-guided intensive meditation-based intervention (iMI) plus general rehabilitation program (GRP)
decrease
PANSS positive symptoms
male inpatients with schizophrenia with treatment-refractory hallucinations and delusions (TRHDs)
-
significantly improved the reduction rates
#2
8-month daily-guided intensive meditation-based intervention (iMI) plus general rehabilitation program (GRP)
decrease
PANSS hallucination/delusion items
male inpatients with schizophrenia with treatment-refractory hallucinations and delusions (TRHDs)
-
significantly improved the reduction rates
#3
8-month daily-guided intensive meditation-based intervention (iMI) plus general rehabilitation program (GRP)
increase
treatment response rates (≥25% reduction) for PANSS total score, positive symptoms, and hallucination/delusion items
male inpatients with schizophrenia with treatment-refractory hallucinations and delusions (TRHDs)
-
significantly increased
#4
8-month daily-guided intensive meditation-based intervention (iMI) plus general rehabilitation program (GRP)
decrease
PANSS total score
male inpatients with schizophrenia with treatment-refractory hallucinations and delusions (TRHDs)
-
significantly reduced
#5
8-month daily-guided intensive meditation-based intervention (iMI) plus general rehabilitation program (GRP)
decrease
PANSS hallucination/delusion items
male inpatients with schizophrenia with treatment-refractory hallucinations and delusions (TRHDs)
-
significantly reduced
#6
8-month daily-guided intensive meditation-based intervention (iMI) plus general rehabilitation program (GRP)
increase
SF-36 physical activity
male inpatients with schizophrenia with treatment-refractory hallucinations and delusions (TRHDs)
-
increasing scores
#7
8-month daily-guided intensive meditation-based intervention (iMI) plus general rehabilitation program (GRP)
increase
FFMQ mindfulness skills
male inpatients with schizophrenia with treatment-refractory hallucinations and delusions (TRHDs)
-
increasing scores
#8
8-month daily-guided intensive meditation-based intervention (iMI)
decrease
persistent hallucinations/delusions
patients with TRHDs
-
benefits
#9
8-month daily-guided intensive meditation-based intervention (iMI)
increase
health-related quality of life (QoL)
patients with TRHDs
-
enhancing
#10
longer iMI duration
increase
treatment outcomes
patients with TRHDs
-
yields superior treatment outcomes
#11
Abstract

AIM: This study investigated the impact of an 8-month daily-guided intensive meditation-based intervention (iMI) on persistent hallucinations/delusions and health-related quality of life (QoL) in male inpatients with schizophrenia with treatment-refractory hallucinations and delusions (TRHDs). METHODS: A randomized controlled trial assigned 64 male inpatients with schizophrenia and TRHD equally to an 8-month iMI plus general rehabilitation program (GRP) or GRP alone. Assessments were conducted at baseline and the third and eighth months using the Positive and Negative Syndrome Scale (PANSS), 36-Item Short Form-36 (SF-36), and Five Facet Mindfulness Questionnaire (FFMQ). Primary outcomes measured PANSS reduction rates for total score, positive symptoms, and hallucinations/delusions items. Secondary outcomes assessed PANSS, SF-36, and FFMQ scores for psychotic symptoms, health-related QoL, and mindfulness skills, respectively. RESULTS: In the primary outcome, iMI significantly improved the reduction rates of PANSS total score, positive symptoms, and hallucination/delusion items compared with GRP at both the third and eighth months. Treatment response rates (≥25% reduction) for these measures significantly increased in the iMI group at the eighth month. Concerning secondary outcomes, iMI significantly reduced PANSS total score and hallucination/delusion items, while increasing scores in physical activity and mindfulness skills at both the third and eighth months compared with GRP. These effects were more pronounced with an 8-month intervention compared with a 3-month intervention. CONCLUSIONS: An iMI benefits patients with TRHDs by reducing persistent hallucinations/delusions and enhancing health-related QoL. Longer iMI duration yields superior treatment outcomes.

Medical Subject Headings (MeSH)
HumansMaleSchizophreniaDelusionsQuality of LifeMeditationInpatientsHallucinations
Study Links
Quality Scores
SafetyNot Assessed
Efficacy85/10
Quality90/10
Citation Metrics
Total Citations1
Citations/Year1.0
Research Impact Scores
APT Score0.50
Weight Score2.80
Normalized Score0.72
Related Supplements